Novocure Q3 2026 Earnings - NOVOCURE LTD

Financial Performance:

• Q3 2026 net revenue reached a record $193 million, up 16% year-over-year, driven by a 19% increase in active patients and a one-time $4 million benefit from higher US/Germany approval rates, partially offset by a $2 million foreign exchange headwind.
• Full-year 2026 net revenue guidance raised to $736–$743 million, representing 12–13% growth, including $30–$34 million from Optune Lua and Optune Pax.
• Gross margin improved to 77% in Q3 from 73% in the prior year, with guidance to maintain margins in the mid-to-high 70s through Q4 2026 due to supply chain efficiencies.
• Operating expenses decreased: Sales & marketing fell 9% to $53 million, and G&A fell 5% to $44 million, primarily due to lower share-based compensation; R&D increased 8% to $58 million driven by Keynote D58 enrollment.
• Net loss narrowed significantly to $10 million (EPS $0.09) from $37 million in Q3 2025; EBITDA loss improved to $2 million from $32 million.
• Adjusted EBITDA turned positive at $16 million in Q3 versus a $3 million loss in the prior year; full-year 2026 Adjusted EBITDA guidance updated to $24–$34 million.
• Cash and investment balance as of September 30, 2026, stood at $463 million.

Guidance and Future Outlook:

• Management reaffirmed a long-term vision of double-digit top-line growth and profitability, targeting cash flow breakeven as the next step after achieving Adjusted EBITDA breakeven.
• Q4 2026 revenue guidance implies $185–$192 million, reflecting a seasonal step-down from Q3's record performance due to the absence of the $4.4 million one-time benefit and preparation for 2027 launches.
• 2027 outlook includes anticipated launches for Optune Maya in the US and Optune Pax reimbursement in Japan, with expectations for the US Optune Pax business to return to growth.
• R&D expenses are expected to be flat to slightly declining in 2027 as large Phase 3 trials (Keynote D58, Luna 2) conclude, barring new major trial initiations.
• Management anticipates a wave of recurrence in pancreatic cancer patients later in the year, creating an opportunity for Optune Pax/TTF adoption.

Business Segments and Product Lines:

• OptuneGEO (GBM): Active patient count reached a record 4,729 (up 11% YoY); PMA application for brain metastases (OptuneMaya) remains under review with FDA, targeting a decision by year-end and launch in early 2027. Keynote D58 trial (combining TTFs with pembrolizumab) on track to complete enrollment by year-end.
• OptuneLua (Japan): Demonstrated strong momentum with 255 active patients globally ($8M revenue) and 110 patients in Japan ($4M revenue); priced similarly to OptuneGEO. OptunePax approved in Japan with reimbursement expected in H1 2027.
• OptunePax (PDAC): 276 active patients with $3.7M revenue; launch in the US has slowed due to competition and practice capacity constraints but remains committed to the locally advanced indication.
• Strategic Trials: Announced Panova-5 and Panova-6 trials to evaluate OptunePax in combination with KRAS inhibitors (VeriSTEM and Deraxan RACIB) in H1 2027.

Market and Competitive Landscape:

• Competition: US OptunePax launch facing significant headwinds from the new KRAS inhibitor Deraxan RACIB, causing "practice overwhelm" due to reimbursement appeals and patient skin irritation management.
• Market Dynamics: Japan identified as a key growth driver with higher incidence rates for pancreatic and lung cancers compared to GBM; expected to become the second-largest market behind the US.
• Adoption: Strong physician interest noted in OptunePax at ESMO; focus on NCCN guideline updates for pancreatic cancer to drive payer inclusion and reimbursement in the US.
• Pipeline: Diversification strategy expanding into brain metastases and multiple pancreatic cancer indications to reduce reliance on the single GBM franchise.

Risks and Challenges:

• Launch Execution: Slowing prescription rates for OptunePax in the US due to the novelty of KRAS inhibitor launches and the logistical burden placed on practices regarding training and reimbursement.
• Clinical Uncertainty: Dependency on future trial data (D58, Panova trials) to establish TTFs as standard of care or optimal combinations in evolving PDAC landscapes.
• Financial Volatility: Potential fluctuations in Adjusted EBITDA quarter-over-quarter and revenue guidance, particularly in Q4 and during the transition to 2027 launches.
• Regulatory: Pending FDA decision on OptuneMaya PMA application by year-end.

Management Commentary and Tone:

• Tone described as "confident" and "positive," emphasizing record commercial execution and progress toward profitability despite segment-specific headwinds.
• Executive Chairman Bill Doyle and CEO Frank Leonard emphasized the company's "fast" path to profitability and the structural efficiency gains made.
• Management acknowledged the temporary nature of the OptunePax US slowdown, framing it as a "noise" issue related to market disruption rather than a lack of clinical value.
• Strong emphasis on the strategic value of the VeriSTEM collaboration to validate TTFs in the KRAS inhibitor era.

Analyst Questions and Answers:

• BJ Kumar (Evercore ISI): Asked about the sustainability of Adjusted EBITDA improvements; CFO confirmed commitment to breakeven but cautioned against straight-line quarter-over-quarter expectations due to Q4 seasonality and 2027 launch prep.
• Larry Beagleson (Wells Fargo): Inquired about 2027 growth targets and Japan timeline; Management confirmed double-digit growth aspirations and Japan reimbursement for Pax in Q1 2027.
• Jason Bedner (Piper Sandler): Asked about OptunePax patient retention and R&D trends; Frank Leonard clarified that patients are not switching to Deraxan in large numbers and that R&D will plateau or decline post-2026 as major trials close.
• Jessica Fye (JPMorgan): Questioned the Q4 revenue guidance step-down; CFO explained the math regarding the removal of Q3's one-time benefits.
• Kevin DeGieter (Leidenberg-Thalman): Asked about the specific learn goals of the VeriSTEM trials; Dr. Weinberg highlighted feasibility, tolerability, and the potential synergistic effect on downstream transcription factors, noting preclinical data supports the combination.

Other Key Points:

• NovoCure's "three-step" profitability path (Adjusted EBITDA breakeven → Cash flow breakeven → Net income breakeven) was completed for the first step in Q3 2026.
• The company is actively working to reset price levels in Japan to match or exceed US pricing for GBM products.
• Management highlighted the structural changes in the organization to support larger patient populations while controlling operating expenses.
• The Q3 2026 results represent the strongest Adjusted EBITDA and net revenue quarters in over four years.